Followers | 3 |
Posts | 766 |
Boards Moderated | 1 |
Alias Born | 06/27/2006 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, April 27, 2010 4:50:14 PM
NexMed Appoints Dr. Stephen B. Howell, World Renowned Key Opinion Leader in Oncology as Chairman of Its Scientific Advisory Board
Press Release Source: NexMed, Inc. On Tuesday April 27, 2010, 4:40 pm
SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM - News), a specialty CRO and a developer of products based on the NexACT® technology, today announced the appointment of Stephen B. Howell, M.D., as Chairman of its Scientific Advisory Board.
Commenting on today’s news, Dr. Bassam Damaj, Chief Executive Officer of NexMed, noted, “We are very pleased to welcome Steve as Chairman of our Scientific Advisory Board. He is recognized as a world-class, key opinion leader in oncology and his expertise will be especially valuable as we continue the development of our cancer therapies.”
Dr. Howell currently serves as a medical oncologist and Professor of Medicine at the University of California, San Diego. He also serves as Associate Director for Clinical Research and Director of the Cancer Therapeutics Training Program at the Moores Comprehensive Cancer Center at the University of California, San Diego, and runs the Clayton Foundation Drug Resistance Laboratory at the Cancer Center. During his career, Dr. Howell has co-founded three pharmaceutical companies, including DepoTech (1989), Beacon Laboratories (1995), and Targa Pharmaceuticals (2003), serving as Medical Director of each.
Dr. Howell holds a number of patents for his innovative work in chemotherapeutics, drug-delivery systems, and diagnostic assays and is the recipient of numerous awards, including the Milken Family Medical Foundation Award for Outstanding Work in the Field of Cancer Research, a presidential citation from the American Head and Neck Society, and a Fogarty Senior International Fellowship. He is currently one of the main organizers of the American Association of Cancer Research.
Dr. Howell is a graduate of Harvard Medical School and is board certified in internal medicine and medical oncology. He completed his internship, residency, and medical oncology training at the Massachusetts General Hospital, the University of California, San Francisco, and the Dana Farber Cancer Institute, respectively. He completed his research training at the National Institutes of Health.
http://finance.yahoo.com/news/NexMed-Appoints-Dr-Stephen-B-bw-3896121677.html?x=0&.v=1
Recent SEEL News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 08:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:05:35 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/31/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:01:36 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 08:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 01:00:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 03:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:00:41 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:32:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:50:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:39:18 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/06/2024 10:26:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 11:04:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/30/2024 11:05:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:46:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:13 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/02/2024 01:10:24 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM